39,283 Amgen Inc. $AMGN Shares Acquired by IFP Advisors Inc

IFP Advisors Inc boosted its stake in Amgen Inc. (NASDAQ:AMGN) by 478.1% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 47,499 shares of the medical research company’s stock after buying an additional 39,283 shares during the period. IFP Advisors Inc’s holdings in Amgen were worth $20,021,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of AMGN. MW Advisory LLC bought a new position in shares of Amgen in the second quarter valued at approximately $1,054,000. Baird Financial Group Inc. increased its stake in shares of Amgen by 1.6% during the second quarter. Baird Financial Group Inc. now owns 339,825 shares of the medical research company’s stock valued at $123,057,000 after acquiring an additional 5,496 shares during the period. Integrated Advisors Network LLC raised its holdings in Amgen by 50.5% during the first quarter. Integrated Advisors Network LLC now owns 18,941 shares of the medical research company’s stock worth $6,664,000 after purchasing an additional 6,356 shares in the last quarter. KBC Group NV raised its holdings in Amgen by 51.7% during the second quarter. KBC Group NV now owns 382,676 shares of the medical research company’s stock worth $138,574,000 after purchasing an additional 130,497 shares in the last quarter. Finally, Nilsine Partners LLC bought a new stake in Amgen during the second quarter worth approximately $3,329,000. Institutional investors own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

AMGN has been the subject of a number of research analyst reports. Canaccord Genuity Group upped their target price on Amgen from $366.00 to $384.00 and gave the stock a “hold” rating in a research report on Wednesday, August 5th. Barclays lifted their price target on Amgen from $360.00 to $380.00 and gave the company an “equal weight” rating in a research report on Friday, August 14th. Cantor Fitzgerald boosted their price objective on Amgen from $400.00 to $440.00 and gave the stock a “neutral” rating in a research note on Monday, October 5th. Weiss Ratings raised Amgen from a “buy (b)” rating to a “buy (b+)” rating in a research note on Thursday, October 8th. Finally, Piper Sandler upped their price objective on Amgen from $427.00 to $457.00 and gave the company an “overweight” rating in a report on Thursday, August 20th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, sixteen have assigned a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $387.93.

Amgen Stock Down 0.4%

NASDAQ AMGN opened at $432.49 on Friday. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13. The company’s 50 day simple moving average is $415.54 and its 200 day simple moving average is $374.76. Amgen Inc. has a 12 month low of $288.00 and a 12 month high of $447.03. The company has a market capitalization of $233.82 billion, a P/E ratio of 26.88, a PEG ratio of 3.17 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, beating the consensus estimate of $5.62 by $0.67. The business had revenue of $10.05 billion during the quarter, compared to analyst estimates of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The business’s quarterly revenue was up 9.5% on a year-over-year basis. During the same period in the prior year, the business earned $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Equities research analysts expect that Amgen Inc. will post 22.94 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, September 11th. Shareholders of record on Friday, August 21st were issued a $2.52 dividend. The ex-dividend date of this dividend was Friday, August 21st. This represents a $10.08 annualized dividend and a dividend yield of 2.3%. Amgen’s dividend payout ratio is currently 62.65%.

Insider Buying and Selling at Amgen

In other news, SVP Nancy Grygiel sold 2,970 shares of the stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the sale, the senior vice president owned 7,340 shares in the company, valued at approximately $2,951,854.40. This represents a 28.81% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Rachna Khosla sold 2,000 shares of the stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total value of $825,140.00. Following the sale, the senior vice president owned 6,404 shares of the company’s stock, valued at $2,642,098.28. This trade represents a 23.80% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 6,222 shares of company stock worth $2,540,926 in the last ninety days. 0.85% of the stock is owned by corporate insiders.

Amgen Company Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.